Back to Screener

Healthcare

Alnylam Pharmaceuticals, Inc.(ALNY)

Live Price

Offline

$293.55

-0.17% today

Window Change

-7.91%

Window

May 29, 2026 โ†’ Jun 18, 2026

Market Cap
$39.75B
Revenue Growth
+65.2%
EPS Growth
+209.6%
Dividend Yield
0.0%
Sparse coverage

Historical coverage is still filling in

This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.

Coverage: 15 bars ยท May 29, 2026 โ†’ Jun 18, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Alnylam Pharmaceuticals, Inc. (ALNY) is a Healthcare stock with a market cap of $39.75B. The stock last traded around $293.55 and down 7.9% across the available one-year price window (May 29, 2026 โ†’ Jun 18, 2026). Baseline metrics include revenue growth of +65.2%, EPS growth of +209.6%, a dividend yield of 0.0%. What stands out right now is revenue +65.2%, EPS +209.6%, free cash flow +1192.7% with operating margin 17.5% and ROIC 19.7%. Valuation already assumes a fairly strong business story at P/E 68.6 and price/sales 9.3. Stock Foundry combines ALNY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Edge

ALNY vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

ALNY

โ€”

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

ALNY Max Drawdown

-8.41%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for ALNY and SPY.

Calendar-year return history is still loading or unavailable.

Unable to load analyst forecasts.

Timed out loading forecasts for ALNY

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.